Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: A nationwide cohort study

BMJ Open

Volumn 2, Issue 3, 2012, Pages

  Jimenez Solem, Espen ^a,b   Andersen, Jon Traerup ^a,b   Petersen, Morten ^a,b   Broedbaek, Kasper ^a,b   Jensen, Jonas Krogh ^c   Afzal, Shoaib ^a,b   Gislason, Gunnar H ^c   Torp Pedersen, Christian ^c,d   Poulsen, Henrik Enghusen ^a,b,d  

^a Rigshospitalet   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; DENMARK; DIGESTIVE SYSTEM MALFORMATION; DRUG EXPOSURE; FEMALE; FIRST TRIMESTER PREGNANCY; GENITAL MALFORMATION; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; LIMB MALFORMATION; MEDICAL RECORD REVIEW; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREGNANT WOMAN; PROGENY; PUERPERAL DEPRESSION; REGISTER; RISK;

EID: 84863672577     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001148     Document Type: Article

References (45)

1. Bennett HA, Einarson A, Taddio A, et al. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004;103:698-709. (Pubitemid 40459031)
2. Chatillon O, Even C. [Antepartum depression: prevalence, diagnosis and treatment] (In French). Encephale 2010;36:443-51.
3. Ververs T, Kaasenbrood H, Visser G, et al. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006;62:863-70. (Pubitemid 44521435)
4. Cooper WO, Willy ME, Pont SJ, et al. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007;196:544-5.
5. Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008;198:194-5.
6. Alwan S, Reefhuis J, Rasmussen SA, et al; Prevention study TNBD. Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol 2011;51:264-70.
7. Bakker MK, Kolling P, van den Berg PB, et al. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 2008;65:600-6. (Pubitemid 351365128)
8. Wichman CL, Fothergill A, Moore KM, et al. Recent trends in selective serotonin reuptake inhibitor use in pregnancy. J Clin Psychopharmacol 2008;28:714-16.
9. Alwan S, Reefhuis J, Rasmussen SA, et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356:2684-92. (Pubitemid 47001036)
10. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-83. (Pubitemid 47001035)
11. Malm H, Artama M, Gissler M, et al. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011;118:111-20.
12. Bakker MK, Kerstjens-Frederikse WS, Buys CH, et al. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 2010;88:94-100.
13. Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007;80:18-27.
14. Cole JA, Ephross SA, Cosmatos IS, et al. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:1075-85. (Pubitemid 350020060)
15. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008;66:695-705.
16. Kallen BA, Otterblad OP. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007;79:301-8. (Pubitemid 46980405)
17. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569.
18. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;40:1723-33.
19. Wichman CL, Moore KM, Lang TR, et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clinic Proc 2009;84:23-7.
20. Wogelius P, Norgaard M, Gislum M, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006;17:701-4. (Pubitemid 44655607)
21. Wurst KE, Poole C, Ephross SA, et al. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010;88:159-70.
22. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005;106:1289-96. (Pubitemid 41668948)
23. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998;279:609-10. (Pubitemid 28110208)
24. Ramos E, St-Andre M, Rey E, et al. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry 2008;192:344-50. (Pubitemid 351692378)
25. Einarson A, Choi J, Einarson TR, et al. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 2009;54:242-6.
26. Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007;16:1086-94. (Pubitemid 350020061)
27. Oberlander TF, Warburton W, Misri S, et al. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008;83:68-76. (Pubitemid 351317794)
28. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002;159:2055-61. (Pubitemid 35423865)
29. Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006;194:961-6.
30. Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999;55:503-8. (Pubitemid 29446550)
31. Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006;21:221-2. (Pubitemid 43294548)
32. Lennestal RM, Kallen B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 2007;27:607-13. (Pubitemid 351339448)
33. Pedersen CB, Gotzsche H, Moller JO, et al. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006;53:441-9. (Pubitemid 44816920)
34. Knudsen LB, Olsen J. The Danish medical birth registry. Dan Med Bull 1998;45:320-3. (Pubitemid 28313542)
35. Sorensen HT, Hansen I, Ejlersen E, et al. Identification of patients treated with strong analgesics: an assessment of two Danish information systems with respect to epidemiological research. J Med Syst 1996;20:57-65. (Pubitemid 26118717)
36. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997;44:445-8. (Pubitemid 27382061)
37. Statistics Denmark. Containing Detailed Statistical Information on the Danish Society. http://www.dst.dk/en (accessed Mar 2012).
38. Andersen TF, Madsen M, Jorgensen J, et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46:263-8. (Pubitemid 29299976)
39. European Surveillance of Congenital Anomalies. EUROCAT Guide 1.3 and Reference Documents. Newtownabbey Co Antrim. University of Ulster, 2005. http://www.eurocat-network.eu/content/EUROCATGuide-1.3.pdf (accessed Mar 2012).
40. Fosbol EL, Gislason GH, Jacobsen S, et al. The pattern of use of nonsteroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol Drug Saf 2008;17:822-33.
41. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-7.
42. Kornum JB, Nielsen RB, Pedersen L, et al. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010;2:29-36.
43. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clin Ther 2007;29:918-26. (Pubitemid 47223423)
44. de Jong van den Berg LT, Feenstra N, Sorensen HT, et al. Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. European Medicine and Pregnancy Group. Teratology 1999;60:33-6. (Pubitemid 29338853)
45. Olesen C, Sondergaard C, Thrane N, et al. Do pregnant women report use of dispensed medications? Epidemiology 2001;12:497-501. (Pubitemid 32761987)